Our Achievements
Positions of researchers as of February, 2015
【Medical devices】
Development of Real-Time Tumor Tracking radiation therapy
Professor Hiroki SHIRATO, M.D., Ph.D.
［Department of Radiology, Hokkaido University Graduate School of Medicine］
| Experimentally developed products |
Real-time Tumor-Tracking Proton Beam Therapy System・Cone Beam CT (CBCT) ・ Short Range Proton Beam Therapy Equipment |
| Target illnesses |
Hard tumor ・Brain tumor |
| Features |
This treatment employs proton beams, particle beams accelerated in a synchrotron to irradiate target tumor. With proton beam therapy, it is possible to reduce the unnecessary irradiation to the healthy tissues surrounding target tumor compared to conventional X-ray therapy. It is especially effective for treatments where avoiding irradiation to organ at risk or surrounding healthy tissues are necessary or required. With the physical properties of proton beams and advantages of spot-scanning irradiation techniques, it is possible to create three-dimensional dose distribution which finely fits the target volume as compared to the conventional method. It also enables delivery of large doses of radiation to the target tumor and limits the irradiation to the healthy tissues around the target tumor. With the improvement with local control of circumscriptum and locally advanced malignant tumors, cure rate is expected to improve and side effects are expected to be lessened. Further, as it enables the control of the neutron generation, it is expected to reduce the incidence of second primary cancer in a long term.
|
【Medical devices】
PET diagnostic imaging using 11C-labelled methionine
Professor Nagara TAMAKI, M.D., Ph.D.
［Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine］
| Experimentally developed products |
Methionine Synthesis Module (C-MET100) |
| Target illnesses |
Brain tumor |
| Features |
|
【Medical devices】
Development of minimally invasive surgery supporting system
Professor Seiji YAMAMOTO, M.D., Ph.D.
［Medical Photonics Research Center, Hamamatsu University School of Medicine］
| Device |
Minimally Invasive Surgery Supporting System |
| Indication |
Diseases which Head and Neck Endoscope Surgery is applicable |
| Features |
Conventional endoscopic surgery involves anatomical positioning which heavily relies on surgeon’s experience and intuition, a monocular endoscopic display without stereoscopic effects, and manipulation procedures that are different from single-handed microscopic surgery. It makes it difficult to introduce microsurgery into the endoscopic surgery. The developed endoscopic surgery navigator automatically tracks patients’ movements without antenna, displays the tip location of surgical instruments, and determines and displays the core position on the endoscope observation field without distance measuring equipment. The stereoscopic endoscope for surgery incorporating features of both endoscope and microscope enables reproduction of surgery with surgical microscope. By adding microscope navigation function which provides detail information of local structure, safer and reliable minimally invasive surgery can be put it into practice.
|
【Medicines】
Intravenous infusion of autologous mesenchymal stem cells from bone marrow for stroke patients Professor Osamu Honmou, M.D., Ph.D.
［Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine］
| Experimentally developed products |
Autologous Mesenchymal Stem Cells from the Bone Marrow (STR01) |
| Target illnesses |
・All supratentorial cerebral infarction (except lacunar infarction) ・Grade 4 or 5 in the modified Rankin Scale ・Age between 20 to 80 |
| Features |
・Develop an investigational new drug (Intravenous infusion of autologous mesenchymal stem cells from bone marrow) as a product for use in medicine
(1) Dose form code: “Injection C1”
(2) Pharmacotherapeutic classification code: “other biologics 639”
(3) Administration route code: “Intravenous injection 21”
・Completed preclinical tests (GLP, non-GLP) after pharmaceutical strategy consultations with the PMDA.
・Completed GMP fieldwork for the CPC.
・Details of production and administration.
(1)Collection of the bone marrow from iliac crests from stroke patients under local anesthesia.
(2)Isolating target cells from the bone marrow at the CPC, and culturing and multiplying about 10,000 times in about 2 weeks.
(3)Manufacture cell product by enclosing about 1 x 108 cells in a bag (about 40 ml) with GMP standards.
(4)Intravenous infusion of the cell product for about 30 – 60 minutes.
|
【Medicines】
Intravenous infusion of autologous mesenchymal stem cells from bone marrow for spinal cord injury patients. Professor Toshihiko YAMASHITA, M.D., Ph.D.
［Department of Orthopaedic Surgery, School of Medicine, Sapporo Medical University］
| Experimentally developed products |
Autologous Mesenchymal Stem Cells from the Bone Marrow (STR01) |
| Target illnesses |
Spinal cord injury (1)Within 14 days of onset (2)Site of the main damage to the spinal cord in the cervical spinal cord. (3)Partial damage to the spinal cord (4)Classified under A~C of the ASIA impairment scale (5)Ages between 20 to 70 |
| Features |
・Develop an investigational new drug (Intravenous infusion of autologous mesenchymal stem cells from bone marrow) as a product for use in medicine
(1) Dose form code: “Injection C1”
(2) Pharmacotherapeutic classification code: “other biologics 639”
(3) Administration route code: “Intravenous injection 21”
・Completed preclinical tests (GLP, non-GLP) after pharmaceutical strategy consultations with the PMDA
・Completed GMP fieldwork for the CPC
・Details of production and administration
(1)Collection of the bone marrow from iliac crests from spinal cord injury patients under local anesthesia
(2)Isolating target cells from the bone marrow at the CPC, and culturing and multiplying about 10,000 times in about 2 weeks
(3)Manufacture cell product by enclosing about 1 x 108 cells in a bag (about 40 ml) with GMP standards
(4)Intravenous infusion of the cell product for about 30 – 60 minutes
|
【Medicines】
Development of a new drug for the treatment of inflammatory bowel diseases using probiotic-derived polyphosphate
Associate Professor Mikihiro FUJIYA, M.D., Ph.D.
［Department of Medicine, Division of Gastroenterology and Hematology/Oncology, Asahikawa Medical University］
| Experimentally developed products |
Long-chain polyphosphate |
| Target illnesses |
Inflammatory bowel diseases |
| Features |
・This study established that long-chain polyphosphate secreted from new lactic acid bacteria works effectively to protect the bowels, a first in the world (international patent applied for: PCT/JP2011/057689).
・Long-chain polyphosphate has anti-inflammatory effects and also fibrosis improvement effects in intestinal inflammation models.
・There are no commercially available anti-inflammation and bowel protecting drugs using bacterially-derived substances, as well as there are no competitive or similar products.
・In preclinical tests, it was demonstrated that the proposed new drug is more effective than 5-ASA, the standard drug used in the treatment.
|
【Medical devices】
Wearable Airborne Ultrasound Doppler System for Urodynamics Study A Novel Device Development and Validation.
Lecturer Seiji MATSUMOTO, M.D., Ph.D.
［Department of Medicine, Division of Renal and Urologic Surgery, Asahikawa Medical University ］
| Achievement |
Airborne ultrasound CW-Doppler system for new UFM device
|
| Target application |
All illnesses involving voiding dysfunction (lower urinary tract dysfunction): for example, benign prostatic hyperplasia, neurogenic bladder, overactive bladder,etc. Application may include user’s self-management of own health. |
| Features |
Finger mounted Doppler sensor acquires Doppler echo and spectrum of running urea drop, to show flow pattern and to make quantitative measurement.
|
【Medical devices】
Development and Clinical Application of Color-Fluorescence Endscopic System.
Professor Yoshinobu Ohsaki, M.D., Ph.D.
［Asahikawa Medical University Hospital / Respiratory Center］
| Experimentally developed products |
Color-Fluorescence Endoscopic System, Fluorescence Endoscopy |
| Target illnesses |
Lung cancer・tumors of the pleura |
| Features |
Advantages and challenges of the Color-Fluorescence Endoscopic System:
1. Advantages and prospects of fluorescence endoscopy using the Color-Fluorescence Endoscopic System
◎Improving sensitivity of the diagnosis of cancers by fluorescence endoscopy
◎Color tone of the fluorescence: it may enable observations of blood, features of lesions, and local fluorescent diagnostic features and antibodies
◎It can be used as an endoscope for digestive organs, thoracoscope as well as a laparoscope.
◎Potential for marketing outside Japan
2. Features of a device to observe the faint color fluorescence of the human body – under development at Asahikawa Medical University since 2000
☑ Sensitive color camera: Cooled CCD, highly electricity-sensitive, noise reduction, small and handy
☑ Improvements in resolution: higher density picture element, high-definition vision, and moire prevention
☑ High-power pumping unit: LED pumping unit, white LED light source (CCS, Inc.)
☑ Improvement in detection rates of early cancer lesions: finding with the clinical study by the first generation prototype
□ Pharmaceutical approval and release
|
Up to February 2015
